
Merck and Eisai Update on LEAP-015 Trial in Gastroesophageal Cancer
Merck and Eisai Update on LEAP-015 Trial in Gastroesophageal Cancer Merck (NYSE: MRK), known as MSD outside of the U.S. and Canada, and Eisai have shared results from the Phase 3 LEAP-015 trial, which evaluated the combination of KEYTRUDA® (pembrolizumab),…












